A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

• Status: Recruiting
• Trial end date: 2022-03-21
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

Participant Must:

• Have histologically confirmed invasive ER+, HER2- breast carcinoma

• Be willing and able to provide pre- and on-treatment tumor samples

• Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale

• Have adequate organ function

• Be able to swallow capsules

Exclusion Criteria:

Participant Must Not:

• Have bilateral invasive breast cancer

• Have metastatic breast cancer

• Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy

• Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer

• Have had prior radiotherapy to the ipsilateral chest wall for any malignancy

• Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer

• Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment

• Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)

• Be pregnant or breastfeeding

• Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled

• Have another serious medical condition